Arrhythmia in Pregnancy
Definition
Cardiac arrhythmias occurring during gestation and the immediate postpartum period encompass a wide spectrum from benign ectopy (the most common) to life-threatening ventricular arrhythmias. Management is governed by the dual-patient physiology: treatment decisions must simultaneously optimise maternal hemodynamics and minimise fetal harm. The 2023 HRS Expert Consensus Statement provides the first comprehensive dedicated international guidance for this field.
Key Concepts
Epidemiology
- Overall prevalence in pregnancy-related hospitalisations: 68–166 per 100,000 admissions sources/arrhythmia-pregnancy-hrs-2023 (rating: very high)
- Most common arrhythmias: premature atrial/ventricular ectopy (50–60% of those with palpitations; usually benign) sources/arrhythmia-pregnancy-hrs-2023
- Sustained arrhythmias (68/100,000): AF 27/100,000, SVT 22/100,000, VT 16/100,000, VF 2/100,000 sources/arrhythmia-pregnancy-hrs-2023
- In-hospital mortality with arrhythmia: 5.9% vs 0% without; perinatal complications 36.5% vs 21.8% sources/arrhythmia-pregnancy-hrs-2023
- Arrhythmias more frequent in older mothers, Black women (116 vs 73/100,000), and those with structural heart disease or congenital heart disease sources/arrhythmia-pregnancy-hrs-2023
- AF increasingly the most common newly diagnosed sustained arrhythmia, driven by rising maternal age, obesity, hypertension, and CHD survival sources/arrhythmia-pregnancy-hrs-2023
- Only 10% of palpitation episodes during pregnancy have an arrhythmia documented on 24-hour Holter; most are benign sources/arrhythmia-pregnancy-hrs-2023
Pathophysiology of Arrhythmogenesis
- Hemodynamic: Blood volume ↑50% (up to 100% in twin pregnancies) → chamber dilation → stretch-activated ion channels → spatial dispersion of refractoriness and shortened refractoriness sources/arrhythmia-pregnancy-hrs-2023
- Hormonal: Estradiol and progesterone increase adrenergic receptor number/responsiveness; chamber enlargement lengthens reentrant pathways sources/arrhythmia-pregnancy-hrs-2023
- Autonomic: Progressive shift from vagal to sympathetic dominance → HR ↑10–20 bpm → predisposes to new or worsened arrhythmias sources/arrhythmia-pregnancy-hrs-2023
Overarching Principles of Management
- Multidisciplinary care (cardio-obstetrics team) is essential: cardiac electrophysiologist, MFM subspecialist, anesthesiologist, neonatologist, pediatric cardiologist (for fetal arrhythmias) sources/arrhythmia-pregnancy-hrs-2023
- Hemodynamically significant arrhythmias should receive prompt, effective therapy (cardioversion, antiarrhythmic drug, or ablation) — care should not be compromised out of fear of fetal harm sources/arrhythmia-pregnancy-hrs-2023
- Shared decision-making must account for risks/benefits to both mother and fetus sources/arrhythmia-pregnancy-hrs-2023
- Genetic testing and counselling recommended for patients with suspected or known IAS sources/arrhythmia-pregnancy-hrs-2023
Procedural Considerations
Cardioversion
- Safe and effective at all stages of pregnancy; same energy levels as non-pregnant patients sources/arrhythmia-pregnancy-hrs-2023
- No modification of technique required; transthoracic impedance unchanged by pregnancy sources/arrhythmia-pregnancy-hrs-2023
- Avoid electrode placement on breast tissue; sterno-apical for VT, antero-posterior for atrial arrhythmias sources/arrhythmia-pregnancy-hrs-2023
- Fetal heart rate monitoring advised once fetal viability reached sources/arrhythmia-pregnancy-hrs-2023
- Should never be withheld due to pregnancy when hemodynamic compromise is present sources/arrhythmia-pregnancy-hrs-2023
Catheter Ablation
- Feasible during pregnancy; ideally deferred to after first trimester sources/arrhythmia-pregnancy-hrs-2023
- Modern 3D mapping systems allow zero-fluoroscopy procedures sources/arrhythmia-pregnancy-hrs-2023
- Typical SVT ablation: fetal radiation well below 50 mGy negligible-risk threshold for lifetime malignancy sources/arrhythmia-pregnancy-hrs-2023
- Lead apron over pelvis: only 3% reduction in fetal radiation — most dose is scatter from maternal thorax, not direct beam; no meaningful protection sources/arrhythmia-pregnancy-hrs-2023
- Complex ablation (e.g., refractory VT): requires cardio-obstetrics team prepared for urgent delivery
Device Implantation
- ICD implantation: follows standard non-pregnant indications; safe with negligible fetal radiation; ideally post-first trimester but maternal safety takes priority sources/arrhythmia-pregnancy-hrs-2023
- Pacemakers: implantable during pregnancy with zero/minimal fluoroscopy when indicated sources/arrhythmia-pregnancy-hrs-2023
Aortocaval Compression
- IVC compression by gravid uterus begins at 20 weeks; severe at term; causes supine hypotensive syndrome sources/arrhythmia-pregnancy-hrs-2023
- Left lateral tilt ≥30° or manual uterine displacement restores hemodynamics sources/arrhythmia-pregnancy-hrs-2023
- Prolonged supine positioning is contraindicated from second trimester onwards sources/arrhythmia-pregnancy-hrs-2023
Anesthesia
- Regional anesthesia preferred; general anesthesia for hemodynamic instability or cardiac procedures sources/arrhythmia-pregnancy-hrs-2023
- Many perioperative drugs prolong QT interval (ondansetron, ketamine, sevoflurane, succinylcholine, epinephrine) — critical awareness in LQTS patients sources/arrhythmia-pregnancy-hrs-2023
- Rapid sequence induction for general anaesthesia; smaller endotracheal tube (≤7.0 mm); difficult airway management sources/arrhythmia-pregnancy-hrs-2023
Antiarrhythmic Drug Principles in Pregnancy
- Pharmacokinetic changes: increased volume of distribution, altered clearance — may require dose increases (especially in third trimester) sources/arrhythmia-pregnancy-hrs-2023
- Select drugs with the longest record of safe use; use lowest effective dose; reevaluate periodically sources/arrhythmia-pregnancy-hrs-2023
- DOACs: contraindicated in pregnancy and breastfeeding sources/arrhythmia-pregnancy-hrs-2023
- Atenolol: best avoided (FDA former category D; fetal growth restriction risk higher than other beta-blockers) sources/arrhythmia-pregnancy-hrs-2023
- Nadolol: highest breast milk concentration among beta-blockers; if breastfeeding, prefer propranolol or metoprolol (unless LQTS stability requires nadolol) sources/arrhythmia-pregnancy-hrs-2023
- Amiodarone: reserve for refractory life-threatening cases; fetal thyroid dysfunction, growth restriction, neonatal adverse effects sources/arrhythmia-pregnancy-hrs-2023
- Verapamil IV: causes significant maternal hypotension; last resort after adenosine and beta-blockers; avoid for fetal arrhythmias sources/arrhythmia-pregnancy-hrs-2023
- Resources: MotherToBaby (mothertobaby.org), Reprotox, Teris; LactMed for lactation safety sources/arrhythmia-pregnancy-hrs-2023
Specific Arrhythmia Management
SVT
- Acute: vagal manoeuvres → adenosine IV → beta-blockers IV → verapamil IV (last resort) → DC cardioversion if unstable sources/arrhythmia-pregnancy-hrs-2023
- Prevention: digoxin, metoprolol, propranolol (robust safety records); atenolol avoided sources/arrhythmia-pregnancy-hrs-2023
- WPW: flecainide or propafenone (block accessory pathway); avoid AV nodal blockers sources/arrhythmia-pregnancy-hrs-2023
- Ablation: ideally pre-pregnancy; during pregnancy use zero-fluoroscopy after first trimester sources/arrhythmia-pregnancy-hrs-2023
- Tachycardia-induced cardiomyopathy from focal AT: EF normalises with treatment; ablation if refractory sources/arrhythmia-pregnancy-hrs-2023
Atrial Fibrillation and Flutter
- DC cardioversion first-line for hemodynamic compromise sources/arrhythmia-pregnancy-hrs-2023
- Rate control: beta-blockers, digoxin, calcium channel blockers sources/arrhythmia-pregnancy-hrs-2023
- Rhythm control: cardioversion ± antiarrhythmic; ibutilide (+ IV magnesium) safe; flecainide oral bolus an option sources/arrhythmia-pregnancy-hrs-2023
- Anticoagulation: CHA₂DS₂-VASc applies; DOACs absolutely contraindicated; use LMWH or warfarin (Table 7 anticoagulation protocol as per mechanical valve management) sources/arrhythmia-pregnancy-hrs-2023
- Catheter ablation: lower threshold for typical AFL; AF ablation generally deferred in pregnancy sources/arrhythmia-pregnancy-hrs-2023
Ventricular Tachycardia
- Hemodynamically unstable: immediate DC cardioversion sources/arrhythmia-pregnancy-hrs-2023
- Idiopathic (RVOT, fascicular): beta-blockers or verapamil; ablation if refractory sources/arrhythmia-pregnancy-hrs-2023
- New VT in pregnancy: always evaluate for SHD, channelopathy, ACM as underlying cause sources/arrhythmia-pregnancy-hrs-2023
Bradycardia / Heart Block
- Pacemaker implantation: standard indications; feasible with minimal/zero fluoroscopy sources/arrhythmia-pregnancy-hrs-2023
- Congenital complete heart block (anti-Ro/SSB antibodies): serial fetal monitoring; dexamethasone controversial sources/arrhythmia-pregnancy-hrs-2023
- Haemodynamically stable AV block with narrow QRS: conservative management at delivery sources/arrhythmia-pregnancy-hrs-2023
Cardiac Arrest in Pregnancy (ACLS)
- Standard BLS/ACLS algorithms apply; coordinated multi-team response critical sources/arrhythmia-pregnancy-hrs-2023
- From ~20 weeks: manual left uterine displacement during CPR (maintains supine position, facilitates airway/defibrillation) sources/arrhythmia-pregnancy-hrs-2023
- No modification of chest compression hand position; standard defibrillation energy sources/arrhythmia-pregnancy-hrs-2023
- IV access preferred above the diaphragm; interosseous humerus as alternative sources/arrhythmia-pregnancy-hrs-2023
- Do not delay maternal defibrillation for fetal monitoring sources/arrhythmia-pregnancy-hrs-2023
- Perimortem/resuscitative hysterotomy: initiate within 5 minutes for viable fetus; perform at site of arrest (no operating room needed); uterine evacuation often improves maternal hemodynamics independently sources/arrhythmia-pregnancy-hrs-2023
Inherited Arrhythmia Syndromes (IAS) — Overview
- Risk: Pregnancies with maternal IAS have 8× higher fetal stillbirth rate and 2× higher miscarriage rate than normal population sources/arrhythmia-pregnancy-hrs-2023
- Genetic counselling: essential preconception; trained genetic counsellors preferred sources/arrhythmia-pregnancy-hrs-2023
- Delivery planning: three-tier risk-stratified framework (low/medium/high) based on recent events, QTc, arrhythmia type sources/arrhythmia-pregnancy-hrs-2023
- See concepts/LQTS-Pregnancy-Management for LQTS-specific management
- BrS: no clear increase in arrhythmic risk during pregnancy or postpartum in women; treat fever aggressively; avoid www.brugadadrugs.org contraindicated drugs sources/arrhythmia-pregnancy-hrs-2023
- CPVT: maintain beta-blockers; add flecainide if recurrent; management follows non-pregnant recommendations sources/arrhythmia-pregnancy-hrs-2023
Inherited Cardiomyopathies in Pregnancy — the Arrhythmic Side
An inherited cardiomyopathy is an arrhythmic diagnosis as much as a structural one, and pregnancy moves the arrhythmic risk in a direction the structural assessment does not predict (sources/cmp-pregnancy-jaccadv-2026, rating: medium):
- ACM: the third trimester and puerperium are the highest-risk periods. Women who gave birth with previously diagnosed ACM had elevated postpartum ventricular arrhythmia risk — HR 13.74 (95% CI 2.9–63; P=0.001) in the NORDIC ARVC Register — though pregnancy was uneventful for the majority, and the number of prior pregnancies was not associated with arrhythmia risk. 13% of pregnancies in the Johns Hopkins/Dutch registry were complicated by ventricular arrhythmia and 5% by heart failure.
- Secondary-prevention ICD should be implanted before conception, not during pregnancy — HRS 2023 gives this a Class 1 recommendation for ACM with prior ventricular arrhythmia or aborted SCD, and device placement in pregnancy adds procedural and fetal risk. Primary prevention follows the usual thresholds (LVEF ≤35% with NYHA II–III on optimal therapy).
- Antiarrhythmic hierarchy in ACM: beta-blockers first-line; flecainide, sotalol or mexiletine where beta-blockers are contraindicated; amiodarone only for life-threatening arrhythmia, as a single dose; catheter ablation 2a if arrhythmia persists despite drugs.
- HCM: pregnancy is well tolerated (maternal mortality 0.2%), but cardiac myosin inhibitors are absolutely contraindicated for teratogenicity — which pushes LVOTO management toward myectomy before conception rather than a drug during pregnancy.
- DCM: arrhythmic risk tracks ejection fraction, and the medication conversion that pregnancy demands removes most of the therapy that was controlling it.
- Monitoring: ECG, 24-hour ambulatory ECG and NT-proBNP every 3 months, moving to monthly with reduced LVEF, NYHA III–IV or any change in symptoms; telemetry intrapartum and through the immediate postpartum period, with intrapartum electrolyte optimisation.
See concepts/Pregnancy-in-Genetic-Cardiomyopathy for the structural and reproductive-genetics side.
Contradictions / Open Questions
- RCT evidence is almost entirely absent in this field; all drug safety and efficacy data are from registries, retrospective series, and case reports — LOE is predominantly C for most recommendations sources/arrhythmia-pregnancy-hrs-2023
- Optimal anticoagulation strategy for AF in pregnancy is unresolved: current approach extrapolated from mechanical valve protocols; DOAC superiority in non-pregnant AF cannot be applied sources/arrhythmia-pregnancy-hrs-2023
- Lead apron utility: Dogma of pelvic lead shielding is refuted by radiation physics data (only 3% dose reduction) — contrast with widespread clinical practice sources/arrhythmia-pregnancy-hrs-2023
- Perimortem C-section timing: 5-minute goal is rarely achieved in practice; survival reported well beyond this window — suggests goal should be "as soon as possible" rather than a strict cutoff sources/arrhythmia-pregnancy-hrs-2023
- Beta-blocker choice in LQTS breastfeeding: Nadolol is preferred for rhythm stability but concentrates in breast milk; no RCT comparing nadolol vs propranolol in this specific scenario sources/arrhythmia-pregnancy-hrs-2023
- Fetal arrhythmia pharmacotherapy: No prospective randomised trial comparing flecainide vs digoxin vs sotalol has been conducted; all data from retrospective non-randomised studies sources/arrhythmia-pregnancy-hrs-2023
- The ACM postpartum hazard ratio is the largest number in the pregnancy literature and the least stable. HR 13.74 (95% CI 2.9–63) comes from 199 women in a single registry that simultaneously reports pregnancy as uneventful for most — the interval spans an order of magnitude, and no other cohort has reproduced a figure of that size. (sources/cmp-pregnancy-jaccadv-2026, rating: medium)
- "Amiodarone only as a single dose in life-threatening arrhythmia" has no defined dose, duration or threshold, in a population where every alternative is also imperfect and the fetal thyroid is at risk throughout.
Connections
- Related to concepts/Fetal-Arrhythmia — fetal arrhythmia management
- Related to concepts/LQTS-Pregnancy-Management — LQTS-specific risk and management
- Related to concepts/Cardio-Obstetrics — multidisciplinary team framework
- Related to concepts/Antiarrhythmic-Drugs — drug safety profiles in pregnancy
- Related to concepts/Torsades-de-Pointes — LQTS/drug-induced TdP in pregnancy
- Related to concepts/Vasovagal-Syncope — most common syncope type in pregnancy
- Related to concepts/Inappropriate-Sinus-Tachycardia — IST in pregnancy
- Related to concepts/Tachycardia-Induced-Cardiomyopathy — from sustained focal AT
- Related to entities/Long-QT-Syndrome — highest-risk IAS
- Related to entities/Brugada-Syndrome — pregnancy management
- Related to entities/CPVT — pregnancy management
- Related to entities/Atrial-Fibrillation — most common sustained arrhythmia in pregnancy
- Related to entities/Amiodarone — last resort; significant fetal toxicity
- Related to entities/Flecainide — preferred for fetal SVT
- Related to concepts/Adverse-Pregnancy-Outcomes — arrhythmias increase perinatal complications
- Related to concepts/Pregnancy-in-Genetic-Cardiomyopathy — genetic cardiomyopathy as an arrhythmic diagnosis
- Related to entities/ARVC — postpartum ventricular arrhythmia risk